Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.
- Trial name
- MALACHITE 1 (NCT01854697)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir
- Volunteers
- 311 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Heart Failure
Hepatitis C Virus(HCV) Heart and Lung Study
This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.
- Conditions
- Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
- Trial name
- NCT02858180
- Testing
- Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Chronic Hepatitis C(CHC)
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
- Trial name
- NCT01753570
- Testing
- MP-424, RBV(24 weeks), IFN beta(24 weeks)
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Impact of Hepatitis C Virus Variability on Steatosis
Chronic infection by the hepatitis C virus (HCV) is a common cause of liver disease, which may progress to cirrhosis and eventually liver cancer.
- Trial name
- Viro-steatosis (NCT00843076)
- Where
- 6 sites in France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Tours
Hepatitis C
Open-Label Hepatic Impairment Study
This study will be conducted in Hepatitis C positive patients to determine whether the pharmacodynamic effects of PSI-7977 or PSI-352938 are similar to HCV-infected patients with normal hepatic function, which may allow inclusion…
- Trial name
- NCT01497327
- Testing
- PSI-352938, PSI-7977
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, Cirrhosis
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed…
- Trial name
- NCT00048724
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 631 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic Hepatitis C
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.
- Trial name
- NCT01646489
- Testing
- Miravirsen sodium, Telaprevir
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
This prospective, multi-center, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) in participants with previously untreated chronic hepatitis C, genotype 2, 3, 1…
- Trial name
- PEGHOPE (NCT01416610)
- Where
- 10 sites in Austria
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) + vedroprevir (VDV) ± ribavirin (RBV) for 8 weeks in…
- Trial name
- NCT02226549
- Testing
- LDV/SOF, VDV, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Mental Disorders, Drug Addiction
Treatment of Hepatitis C in Psychiatric Patients
Psychiatric disorders or drug addiction are often regarded as contraindications against the use of Interferon-alpha in patients with chronic hepatitis C.
- Trial name
- NCT00751426
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Charite University, Berlin, Germany
Chronic Hepatitis C
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin…
- Trial name
- NCT01517308
- Testing
- pegylated interferon alpha 2a + ribavirin
- Where
- Italy
- Sponsor
- Federico II University
Hepatitis C, Chronic
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)
This study is being done to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-8325 in male hepatitis C virus (HCV)-infected participants. There will be 3 parts to this study.
- Trial name
- NCT01554189
- Testing
- MK-8325
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
HCV Infection, Hepatitis C, Chronic
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
Response to a second-line anti-HCV treatment in non responder patients to a first-line dual therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be potentially effective to treat hepatitis C.
- Trial name
- PEGARI (NCT00221624)
- Testing
- Peginterferon alfa-2a, ribavirin, amantadine
- Where
- France
- Volunteers
- 131 people
- Sponsor
- University Hospital, Bordeaux
Chronic Hepatitis c
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment
- Trial name
- NCT03348059
- Testing
- Direct-acting antiviral therapy
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
- Trial name
- NCT01180790
- Testing
- ACH-0141625 (Sovaprevir), Pegylated Interferon alpha-2a, Ribavirin
- Where
- 18 sites in United States, Belgium
- Volunteers
- 122 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C, Chronic
Combination Therapy for Chronic Hepatitis C Infection
Background: GS-7977, GS-5885, GS-9669, and GS-9451 are new drugs for treating hepatitis C virus (HCV) infection. GS-7977 may help treat the infection when used with other treatments like interferon therapy.
- Trial name
- NCT01805882
- Testing
- Sofosbuvir, Ledipasvir, GS-9669
- Where
- 3 sites in United States
- Volunteers
- 229 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.
- Trial name
- SMART-C (NCT03117569)
- Testing
- glecaprevir (300mg)/pibrentasvir (120mg)
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 380 people
- Sponsor
- Kirby Institute
Hepatitis C, Chronic
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)
This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.
- Trial name
- NCT01425190
- Testing
- Boceprevir
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
- Trial name
- ENDURANCE-2 (NCT02640482)
- Testing
- ABT-493/ABT-530
- Volunteers
- 304 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin
To evaluate the efficacy of pegylated interferon alfa-2a 40 kD (PEGASYS) combination therapy with ribavirin (Copegus)given for 24 or 48 weeks in patients with chronic hepatitis C (CHC) virus infection genotype 2 or 3 who…
- Trial name
- RelapC (NCT00641654)
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Göteborg University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.